Baseline | |
---|---|
Overall gender (N) | |
Male/Female | 40/33 |
Total | 73 |
Age (yrs) | 9.8 ± 4.1 |
Type of AEDs (N) | |
Valproate | 23 |
Oxcarbazepine | 29 |
Valproate + Oxcarbazepine | 21 |
Growth evaluation | |
Height (cm) | 133.5 ± 21.5 |
Height-SDS | -0.2 ± 1.3 |
Weight (kg) | 35.0 ± 17.0 |
Weight-SDS | 0.5 ± 1.8 |
Body mass index-SDS | 1.1 ± 2.6 |
Laboratory studies | |
Aspartate aminotransferase (U/L) | 27.6 ± 7.5 |
Alanine aminotransferase(U/L) | 17.1 ± 7.8 |
Blood urea nitrogen (mg/dL) | 13.0 ± 1.2 |
Creatinine (mg/dL) | 0.5 ± 0.2 |
Alkaline phosphatase (U/L) | 226.8 ± 85.0 |
Total calcium (mg/dL) | 9.5 ± 0.4 |
Free calcium (mg/dL) | 4.9 ± 0.3 |
Phosphorous (mg/dL) | 4.7 ± 0.3 |
Hemoglobin (g/dL) | 13.0 ± 1.2 |
Post-treatment | |
Laboratory studies | |
Serum TRAcP5b (umol/L/min) | 4.8 ± 1.7 |
TRAcP5b-SDS | -1.6 ± 1.2 |
Serum BAP (umol/L/min) | 144.4 ± 73.2 |
BAP-SDS | 1.7 ± 3.7 |
Total calcium (mg/dL) | 9.2 ± 0.3 |
Free calcium (mg/dL) | 4.7 ± 0.3 |